Literature DB >> 21965579

Efficacy of intravenous tissue plasminogen activator in frostbite patients and presentation of a treatment protocol for frostbite patients.

Adam R Johnson1, Heather L Jensen, George Peltier, Eugene DelaCruz.   

Abstract

UNLABELLED: Frostbite can be a devastating and even debilitating injury. Early identification and proper treatment of frostbite is critical in saving digits and limbs. Tissue plasminogen activator (tPA) has been shown to be effective in reducing the number of digits amputated after severe frostbite injury. Nothing has been presented in the podiatric literature regarding the use of tPA in treating frostbite patients for preserving toes and feet. Intravenous tPA and IV heparin were used to treat severe frostbite injuries that did not show improvement after rapid rewarming, had absent Doppler pulses in the distal limb or digits, showed limited or no perfusion by Tc-99 3-phase bone scan, and had no contraindications to use of tPA. All 11 patients included in this study were treated at Hennepin County Medical Center between 2008 and 2010. A total of 73 digits (upper and lower extremity) were considered at risk for amputation after evaluation with Tc-99 bone scan. Of those digits that were affected, 43 were amputated. Intravenous tPA is a safe and effective treatment to reduce the number of digital amputations after severe frostbite injury. The authors' protocol for treating severe frostbite includes the use of tPA. LEVELS OF EVIDENCE: Therapeutic, Level IV.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21965579     DOI: 10.1177/1938640011422596

Source DB:  PubMed          Journal:  Foot Ankle Spec        ISSN: 1938-6400


  10 in total

Review 1.  Frostbite: Spectrum of Imaging Findings and Guidelines for Management.

Authors:  John D Millet; Richard K J Brown; Benjamin Levi; Casey T Kraft; Jon A Jacobson; Milton D Gross; Ka Kit Wong
Journal:  Radiographics       Date:  2016-08-05       Impact factor: 5.333

2.  Treatment of severe frostbite with iloprost in northern Canada.

Authors:  Alexander Poole; Josianne Gauthier
Journal:  CMAJ       Date:  2016-04-04       Impact factor: 8.262

3.  Tissue plasminogen activator prevents mortality from sulfur mustard analog-induced airway obstruction.

Authors:  Livia A Veress; Tara B Hendry-Hofer; Joan E Loader; Jacqueline S Rioux; Rhonda B Garlick; Carl W White
Journal:  Am J Respir Cell Mol Biol       Date:  2013-04       Impact factor: 6.914

4.  Frostbite injuries and our experience treatment in the Samarkand area Uzbekistan.

Authors:  Babur M Shakirov
Journal:  Int J Burns Trauma       Date:  2020-08-15

5.  The Triaging and Treatment of Cold-Induced Injuries.

Authors:  Christoph Sachs; Marcus Lehnhardt; Adrien Daigeler; Ole Goertz
Journal:  Dtsch Arztebl Int       Date:  2015-10-30       Impact factor: 5.594

6.  The Use of tPA in the Treatment of Frostbite: A Systematic Review.

Authors:  Richard L Hutchison; Hannah M Miller; Spencer K Michalke
Journal:  Hand (N Y)       Date:  2018-09-19

7.  Protocoled thrombolytic therapy for frostbite improves phalangeal salvage rates.

Authors:  Rosemary Elizabeth Paine; Elizabeth Noel Turner; Daniel Kloda; Carolyne Falank; Bruce Chung; Damien Wilson Carter
Journal:  Burns Trauma       Date:  2020-04-10

Review 8.  Frostbite: a practical approach to hospital management.

Authors:  Charles Handford; Pauline Buxton; Katie Russell; Caitlin Ea Imray; Scott E McIntosh; Luanne Freer; Amalia Cochran; Christopher He Imray
Journal:  Extrem Physiol Med       Date:  2014-04-22

Review 9.  Use of Intra-arterial Thrombolytic Therapy for Acute Treatment of Frostbite in 62 Patients with Review of Thrombolytic Therapy in Frostbite.

Authors:  Teresa Gonzaga; Kamrun Jenabzadeh; Christopher P Anderson; William J Mohr; Frederick W Endorf; David H Ahrenholz
Journal:  J Burn Care Res       Date:  2016 Jul-Aug       Impact factor: 1.845

10.  Thrombolytic Salvage of the Frostbitten Upper Extremity: A Systematic Review.

Authors:  James Drinane; Adee J Heiman; Joseph A Ricci; Ashit Patel
Journal:  Hand (N Y)       Date:  2020-09-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.